SavedAdd your journal

Journals / BEYOGLU EYE JOURNAL / 2018 / Cilt: 3 - Sayı: 1

Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3-Year Outcomes

İrfan PERENTE
Özgür ARTUNAY
Alper ŞENGÜL
Pages
8–12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The mean number of injections was 3.5±1.1, 2.3±0.9, and 1.7±0.8, at 12, 24, and 36 months, respectively.Conclusion: The results of this study indicated that IVR injections provided a significant long-term visual and anatomical benefit in cases of mCNV with few injections

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The purpose of this study was to report the functional and anatomical results of intravitreal ranibizumab (IVR) injections administered for myopic choroidal neovascularization (mCNV) secondary to pathological myopia.Methods: In this retrospective study, 32 eyes of 32 mCNV patients were evaluated.
📊
Key Findings & Data:The reinjection criteria were a reduction in visual acuity and/or an increase in central macular thickness measured with OCT.Results: The mean age of the patients was 57.7±14.6 years, and the mean axial length was 27.8±1.3 mm.
💡
Conclusion & Impact:The mean number of injections was 3.5±1.1, 2.3±0.9, and 1.7±0.8, at 12, 24, and 36 months, respectively.Conclusion: The results of this study indicated that IVR injections provided a significant long-term visual and anatomical benefit in cases of mCNV with few injections
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The purpose of this study was to report the functional and anatomical results of intravitreal ranibizumab (IVR) injections administered for myopic choroidal neovascularization (mCNV) secondary to pathological myopia.Methods: In this retrospective study, 32 eyes of 32 mCNV patients were evaluated. After a first IVR injection, patients were followed up and treated with an as-needed monthly regime. Best-corrected visual acuity and optic coherence tomography (OCT) findings were evaluated at baseline and then monthly. The reinjection criteria were a reduction in visual acuity and/or an increase in central macular thickness measured with OCT.Results: The mean age of the patients was 57.7±14.6 years, and the mean axial length was 27.8±1.3 mm. The mean visual acuity improved significantly from 46.4±9.7 letters at baseline to 54.1±9.5 letters at the last follow-up visit (p 0.05). The mean number of injections was 3.5±1.1, 2.3±0.9, and 1.7±0.8, at 12, 24, and 36 months, respectively.Conclusion: The results of this study indicated that IVR injections provided a significant long-term visual and anatomical benefit in cases of mCNV with few injections

🔖

Cite This Article

PERENTE, İ., ARTUNAY, Ö., ŞENGÜL, A. (2018). Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3-Year Outcomes. BEYOGLU EYE JOURNAL, Cilt: 3 - Sayı: 1, 8–12. https://ajindex.com/articles/146241

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 2014;157:9–25.e12
  2. Chan NS, Teo K, Cheung CM. Epidemiology and Diagnosis of Myopic Choroidal Neovascularization in Asia. Eye Contact Lens 2016;42:48–55
  3. Neelam K, Cheung CM, Ohno-Matsui K, Lai TY, Wong TY. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res 2012;31:495–525
  4. Ohno-Matsui K. What is the fundamental nature of pathologic myopia? Retina 2017;37:1043–8
  5. Ohno-Matsui K, Lai TY, Lai CC, Cheung CM. Updates of pathologic myopia. Prog Retin Eye Res 2016;52:156–87
  6. Miller DG, Singerman LJ. Natural history of choroidal neovascularization in high myopia. Curr Opin Ophthalmol 2001;12:222–4
  7. Gelisken O, Yalcinbayir O. Retinal Findings and Complications in Pathological Myopia. Ret-Vit 2010;18:108-113
  8. Seko Y, Seko Y, Fujikura H, Pang J, Tokoro T, Shimokawa H. Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest Ophthalmol Vis Sci 1999;40:3287–91
  9. Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2003;87:570–3
  10. Neelam K, Cheung CM, Ohno-Matsui K, Lai TY, Wong TY. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res 2012;31:495–525
  11. Leveziel N, Yu Y, Reynolds R, Tai A, Meng W, Caillaux V, et al. Genetic factors for choroidal neovascularization associated with high myopia. Invest Ophthalmol Vis Sci 2012;53:5004–9
  12. Wakabayashi T, Ikuno Y. Choroidal filling delay in choroidal neovascularisation due to pathological myopia. Br J Ophthalmol 2010;94:611–5
  13. Ruiz-Moreno JM, Montero JA. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol 2002;12:117–22
  14. Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev 2005:CD004765
  15. Özdemir H, Karaçorlu M. Photodynamic Therapy in Patients With Subfoveal Choroidal Neovascularization Secondary to the Pathologic Myopia. Turk J Ophthalmol 2002; 32:769–74 16. Altan T, Acar N, Kapran Z, Unver YB, Ozdogan S. Outcome of photodynamic the